OncLive SOSS

OncLive Insights^®

EP. 1: Introduction to Melanoma

EP. 1: Introduction to Melanoma

EP. 2: Testing and BRAF Mutations in Melanoma

EP. 2: Testing and BRAF Mutations in Melanoma

EP. 3: A Look at the KEYNOTE-054 and COMBI-AD Data

EP. 3: A Look at the KEYNOTE-054 and COMBI-AD Data

EP. 4: Treatment Goals and Patient Decisions in Melanoma

EP. 4: Treatment Goals and Patient Decisions in Melanoma

EP. 5: The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

EP. 5: The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

EP. 6: Molecular Testing in Metastatic Melanoma

EP. 6: Molecular Testing in Metastatic Melanoma

EP. 1: Treatment Approach for R/R Multiple Myeloma

EP. 1: Treatment Approach for R/R Multiple Myeloma

EP. 2: The Rationale for Targeting BCMA in Multiple Myeloma

EP. 2: The Rationale for Targeting BCMA in Multiple Myeloma

EP. 3: DREAMM-2 Trial Efficacy Data and Recent FDA Approval

EP. 3: DREAMM-2 Trial Efficacy Data and Recent FDA Approval

EP. 4: DREAMM-2 Trial Regimen Safety Profile

EP. 4: DREAMM-2 Trial Regimen Safety Profile

EP. 5: Management of Ocular Events From DREAMM-2 Regimen

EP. 5: Management of Ocular Events From DREAMM-2 Regimen

EP. 6: DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

EP. 6: DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

EP. 1: The Optimal Approach to Treating Advanced Melanoma

EP. 1: The Optimal Approach to Treating Advanced Melanoma

EP. 2: Impact of MSLT-II Data on Completion Lymph Node Dissection

EP. 2: Impact of MSLT-II Data on Completion Lymph Node Dissection

EP. 3: Neoadjuvant Melanoma Therapy: Patient Selection

EP. 3: Neoadjuvant Melanoma Therapy: Patient Selection

EP. 4: Importance of Molecular Testing in Stage III Melanoma

EP. 4: Importance of Molecular Testing in Stage III Melanoma

EP. 5: Adjuvant Clinical Trial Data Impact on Treatment Selection

EP. 5: Adjuvant Clinical Trial Data Impact on Treatment Selection

EP. 6: Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma

EP. 6: Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma

EP. 7: Balancing Safety and Efficacy in Adjuvant Therapy

EP. 7: Balancing Safety and Efficacy in Adjuvant Therapy

EP. 8: Short-Term COVID-19 NCCN Recommendations

EP. 8: Short-Term COVID-19 NCCN Recommendations

EP. 9: BRAF-Wild Type vs Mutated Unresectable Melanoma

EP. 9: BRAF-Wild Type vs Mutated Unresectable Melanoma

EP. 10: Metastatic Melanoma Long-Term Survival Data

EP. 10: Metastatic Melanoma Long-Term Survival Data

EP. 11: Long-Term Survival Data in Adjuvant Therapy

EP. 11: Long-Term Survival Data in Adjuvant Therapy

EP. 12: Emerging Treatments for Advanced Melanoma

EP. 12: Emerging Treatments for Advanced Melanoma

EP. 1: The Biology of RCC and Improved Treatment Outcomes

EP. 1: The Biology of RCC and Improved Treatment Outcomes

EP. 2: Tumor Biology in Favorable to Poor-Risk RCC

EP. 2: Tumor Biology in Favorable to Poor-Risk RCC

EP. 3: Improved Outcomes With Novel and Combination Therapies

EP. 3: Improved Outcomes With Novel and Combination Therapies

EP. 4: Risk Assessment and Diagnostic Work-up

EP. 4: Risk Assessment and Diagnostic Work-up

EP. 5: Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

EP. 5: Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

EP. 6: The Role of VEGF TKI Monotherapy

EP. 6: The Role of VEGF TKI Monotherapy

EP. 7: Impact of the Phase 3 CheckMate 9ER Trial on Practice

EP. 7: Impact of the Phase 3 CheckMate 9ER Trial on Practice

EP. 8: The Role of Combination Treatment in RCC

EP. 8: The Role of Combination Treatment in RCC

EP. 9: The Future Treatment Landscape of RCC

EP. 9: The Future Treatment Landscape of RCC

EP. 10: Emerging Therapies for Relapsed/Refractory MRCC

EP. 10: Emerging Therapies for Relapsed/Refractory MRCC

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

EP. 3: Role of Radioiodine Treatment in DTC

EP. 3: Role of Radioiodine Treatment in DTC

EP. 4: Thyrotropin Suppression as DTC Treatment Option

EP. 4: Thyrotropin Suppression as DTC Treatment Option

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

EP. 6: Discussing Iodine-Refractory DTC With Patients

EP. 6: Discussing Iodine-Refractory DTC With Patients

EP. 7: Management of DTC in Clinical Practice

EP. 7: Management of DTC in Clinical Practice

EP. 8: Roles and Communication in Treatment in DTC

EP. 8: Roles and Communication in Treatment in DTC

EP. 9: Understanding Sequencing and What to Look for in DTC

EP. 9: Understanding Sequencing and What to Look for in DTC

EP. 10: Approaching Treatment of Low-Volume DTC

EP. 10: Approaching Treatment of Low-Volume DTC

EP. 11: Multidisciplinary Management for the Treatment of DTC

EP. 11: Multidisciplinary Management for the Treatment of DTC

EP. 12: RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

EP. 12: RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

EP. 13: Sorafenib and Lenvatinib Side Effect Profile and Dosing

EP. 13: Sorafenib and Lenvatinib Side Effect Profile and Dosing

EP. 1: Renal Cell Carcinoma and Novel Therapies

EP. 1: Renal Cell Carcinoma and Novel Therapies

EP. 2: Supportive Care and Systemic Therapy for RCC

EP. 2: Supportive Care and Systemic Therapy for RCC

EP. 3: Supportive Care and Systemic Therapy for RCC

EP. 3: Supportive Care and Systemic Therapy for RCC

EP. 4: Newly Diagnosed RCC: Treatment Planning

EP. 4: Newly Diagnosed RCC: Treatment Planning

EP. 5: Risk Stratification in Renal Cell Carcinoma

EP. 5: Risk Stratification in Renal Cell Carcinoma

EP. 6: mRCC Risk Assessment and Treatment Options

EP. 6: mRCC Risk Assessment and Treatment Options

EP. 7: Treatment Planning and Risk Assessment in mRCC

EP. 7: Treatment Planning and Risk Assessment in mRCC

EP. 8: Supportive Care for mRCC: Current Practices

EP. 8: Supportive Care for mRCC: Current Practices

EP. 9: Selecting Frontline Therapy for mRCC

EP. 9: Selecting Frontline Therapy for mRCC

EP. 10: mRCC: Moving to Second-Line Therapy

EP. 10: mRCC: Moving to Second-Line Therapy

EP. 11: Second-Line Treatment Approaches for mRCC

EP. 11: Second-Line Treatment Approaches for mRCC

EP. 12: Lenvatinib for mRCC

EP. 12: Lenvatinib for mRCC

x